Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges and future directions for multiple sclerosis after the 2024 McDonald diagnostic criteria.

Nature medicine·2026
Same author

Assessing Progression Independent of Relapse Activity in Multiple Sclerosis Using a Patient-Reported Disability Measure and Self-Administered Neuroperformance Outcomes.

Annals of neurology·2026
Same author

Chronological ageing and ovarian reserve in MS: insights from anti-Müllerian hormone and disability progression.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Redefining Multiple Sclerosis: Toward a Biologically Driven Diagnosis.

Neurology·2026
Same author

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis.

Brain : a journal of neurology·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026

Related Experiment Video

Updated: Apr 11, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K

Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

Angela Vidal-Jordana1, Jaume Sastre-Garriga2, Alex Rovira3

  • 1Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, P. Vall d'Hebron 119-129, 08035, Barcelona, Spain.

Journal of Neurology
|June 5, 2015
PubMed
Summary

Brain atrophy is a key indicator of Multiple Sclerosis (MS) progression. This review summarizes brain volume changes in relapsing-remitting MS (RRMS) clinical trials, highlighting its relevance in assessing treatment efficacy.

Keywords:
Brain atrophyInterferonMS therapyMonoclonalOral

More Related Videos

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.4K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.3K

Related Experiment Videos

Last Updated: Apr 11, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.2K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.4K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.3K

Area of Science:

  • Neuroscience
  • Immunology
  • Radiology

Background:

  • Multiple sclerosis (MS) is an immune-mediated central nervous system disease.
  • Brain atrophy, or volume loss, is an early and clinically relevant feature of MS, correlating with disability progression.
  • Automated software tools enable accurate and reproducible measurement of brain volume loss.

Purpose of the Study:

  • To review and summarize data on brain volume changes in patients with relapsing-remitting MS (RRMS).
  • To assess the role of brain volume as an outcome measure in clinical trials for RRMS treatments.
  • To compile findings from clinical trials and observational studies of drugs with positive Phase III outcomes by March 2014.

Main Methods:

  • Systematic review of clinical trials and open-label observational studies.
  • Focus on drugs with positive primary outcomes in at least one Phase III trial.
  • Inclusion of studies reporting brain volume data as a treatment effect measure.

Main Results:

  • Brain volume loss is a significant outcome in MS clinical trials.
  • Automated measurement tools facilitate the assessment of treatment effects on brain atrophy.
  • Data from various RRMS treatments indicate the utility of brain volume as a biomarker.

Conclusions:

  • Brain volume measurement is a crucial endpoint for evaluating therapeutic interventions in MS.
  • The review consolidates evidence on brain volume changes in RRMS treatment studies.
  • Understanding brain atrophy progression is vital for managing MS and predicting patient outcomes.